Journal
ANNALS OF NEUROLOGY
Volume 87, Issue 2, Pages 267-280Publisher
WILEY
DOI: 10.1002/ana.25649
Keywords
-
Categories
Funding
- ADNI (NIH) [U01 AG024904]
- ADNI (Department of Defense) [W81XWH-12-2-0012]
- NIH National Institute on Aging
- NIH National Institute of Biomedical Imaging and Bioengineering
- AbbVie
- Alzheimer's Association
- Alzheimer's Drug Discovery Foundation
- Araclon Biotech
- BioClinica
- Biogen
- Bristol-Myers Squibb Company
- CereSpir
- Cogstate
- Eisai
- Elan Pharmaceuticals
- Eli Lilly and Company
- EuroImmun
- F. Hoffmann-La Roche
- Genentech
- Fujirebio
- GE Healthcare
- IXICO
- Janssen Alzheimer Immunotherapy Research Development
- Johnson & Johnson Pharmaceutical Research Development
- Lumosity
- Lundbeck
- Merck Co
- Meso Scale Diagnostics
- NeuroRx Research
- Neurotrack Technologies
- Novartis Pharmaceuticals Corporation
- Pfizer
- Piramal Imaging
- Servier
- Takeda Pharmaceutical Company
- Transition Therapeutics
- Canadian Institutes of Health Research
Ask authors/readers for more resources
Objective Unawareness, or anosognosia, of memory deficits is a challenging manifestation of Alzheimer disease (AD) that adversely affects a patient's safety and decision-making. However, there is a lack of consensus regarding the presence, as well as the evolution, of altered awareness of memory function across the preclinical and prodromal stages of AD. Here, we aimed to characterize change in awareness of memory abilities and its relationship to beta-amyloid (A beta) burden in a large cohort (N = 1,070) of individuals across the disease spectrum. Methods Memory awareness was longitudinally assessed (average number of visits = 4.3) and operationalized using the discrepancy between mean participant and partner report on the Everyday Cognition scale (memory domain). A beta deposition was measured at baseline using [18F]florbetapir positron emission tomographic imaging. Results A beta predicted longitudinal changes in memory awareness, such that awareness decreased faster in participants with increased A beta burden. A beta and clinical group interacted to predict change in memory awareness, demonstrating the strongest effect in dementia participants, but could also be found in the cognitively normal (CN) participants. In a subset of CN participants who progressed to mild cognitive impairment (MCI), heightened memory awareness was observed up to 1.6 years before MCI diagnosis, with memory awareness declining until the time of progression to MCI (-0.08 discrepant-points/yr). In a subset of MCI participants who progressed to dementia, awareness was low initially and continued to decline (-0.23 discrepant-points/yr), reaching anosognosia 3.2 years before dementia onset. Interpretation A beta burden is associated with a progressive decrease in self-awareness of memory deficits, reaching anosognosia approximately 3 years before dementia diagnosis. ANN NEUROL 2019
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available